Alnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its lead drug, Amvuttra (vutrisiran), for treating the cardiomyopathy of wild-type ...

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

Cantor Fitzgerald said that while the firm “congratulates” Alnylam Pharmaceuticals (ALNY) on last week’s Amvuttra approval, with the stock ...

AMVUTTRA is an RNAi therapeutic that works ... M.D., Chief Medical Officer of Alnylam. “Data showing beneficial effects on cardiac systolic and diastolic function are novel and indicate the ...

Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price upped by research analysts at Scotiabank from ...

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price increased by Stifel Nicolaus from $300.00 to ...

In one study, Alnylam Pharmaceuticals' Amvuttra helped lower the risk of death and heart problems by 28% over three years compared to a placebo. The drug is given as a shot every three months.